Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Frontier Biotechnologies Receives American Patent For Anti-HIV Drug

This article was originally published in PharmAsia News

Executive Summary

Frontier Biotechnologies has received a patent for its new anti-HIV drug Albuvirtide in the U.S., paving the way to enter the global market. To date, the Chongqing firm has patented the drug in more than 10 countries. Since May 2008, Phase I clinical trials of Albuvirtide being conducted in Beijing show positive results for long-acting effects, safety and reduction of virus (PharmAsia News, Sept. 22, 2008). The trial is expected to complete by the third quarter of 2009, to be followed by Phase II and Phase III trials. Frontier Biotechnologies will apply to China's State FDA to market the new drug after completing clinical trials, likely next year. (Click here for more - Chinese Language)

You may also be interested in...



Frontier Biotechnologies’ HIV Drug Enters Phase I Clinical Trials

Frontier Biotechnologies' anti-HIV type 1 Albuvirtide has entered Phase I clinical trials. The new patented drug developed by the Chinese firm shows strong inhibitory effects on HIV and its various index values appear better than other types of anti-HIV drugs on the market. Usage of imported products is at least RMB 80,000 ($11,712) per year, while popular domestic cocktail treatment costs more than RMB 4,000 annually and can lead to liver and kidney side effects. In contrast, Albuvirtide therapy has long-lasting effects of up to 20 days, translating to only one to two administrations per month and less than RMB 4,000 per year. (Click here for more - Chinese Language)

Mylan Bids To Win EU Approval For Upjohn Merger

Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.

IGBA Criticizes Export Restrictions

National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.

UsernamePublicRestriction

Register

SC071843

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel